


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the November 2013 NCCN Trends™ Survey, which focused on Non-Small Cell Lung Cancer. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 835)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with non-small cell lung cancer (NSCLC)? (n = 835)




Q2. When do you test for mutations when treating patients with NSCLC? (n = 527)



Q2. When do you test for mutations when treating patients with NSCLC?


By Geography

■ Prior to front-line therapy
■ Prior to second or later line of therapy



Q2. When do you test for mutations when treating patients with NSCLC?


By Practice Size



Q2. When do you test for mutations when treating patients with NSCLC?


By Practice Setting

- Prior to front-line therapy
- Prior to second or later line of therapy




Q2. When do you test for mutations when treating patients with NSCLC?


By Specialty




Q3. Do you generally conduct a repeat biopsy at disease progression? (n = 524)



Q3. Do you generally conduct a repeat biopsy at disease progression?




Q3. Do you generally conduct a repeat biopsy at disease progression?



Q3. Do you generally conduct a repeat biopsy at disease progression?


By Practice Setting

■ Yes
■ No




Q3. Do you generally conduct a repeat biopsy at disease progression?

By Specialty




Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification? (n = 509)



Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification?

By Geography


- Not at all familiar
- Slightly familiar
- Moderately Familiar
- Very Familiar
- Extremely familiar



Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification?

By Practice Size


- Not at all familiar
- Slightly familiar
- Moderately Familiar
- Very Familiar
- Extremely familiar



Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification?

By Practice Setting


- Not at all familiar
- Slightly familiar
- Moderately Familiar
- Very Familiar
- Extremely familiar




Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification?

By Specialty

- Not at all familiar
- Slightly familiar
- Moderately Familiar
- Very Familiar
- Extremely familiar




Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply)



Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply)

By Geography


- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply)

By Practice Size


- 1 to 3
- 4 to 9
- 10 or more



Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply)

By Practice Setting


■ Academic Setting
■ Community Setting



Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply)

By Specialty

- Medical Oncology
- Radiation Oncology
- Surgical Oncology
- Internal Medicine
- General Surgery
- Other



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.